{"entity":{"id":"community-oncology-networks","kind":"technology","name":"Community oncology and site networks","aka":[],"tldr":"The clinics where most cancer patients are actually treated, increasingly organised into large networks that also run trials.","summary":"In the US, over half of patients are treated in community practices organised by The US Oncology Network (McKesson), OneOncology (TPG/AmerisourceBergen), Florida Cancer Specialists, American Oncology Network, and hospital systems; Sarah Cannon Research Institute (HCA/McKesson JV) and NCI's NCORP bring trials to them. Vertical integration with distributors and payer models (Enhancing Oncology Model) shape drug choice and trial access.","status":"standard-of-care","asOf":"2026-09-08","links":[{"label":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes (JNCI: Journal of the National Cancer Institute 2019)","url":"https://doi.org/10.1093/jnci/djy221"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["ai-trial-matching","oncology-real-world-data"],"targets":[],"drugs":[],"companies":["mckesson-us-oncology","oneoncology","florida-cancer-specialists","sarah-cannon-research-institute"],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Networked practices share EHR, pathways, purchasing, and research infrastructure to deliver care close to home.","strengths":["Access near home","Large trial-eligible populations"],"limitations":["Variable adoption of new biomarker testing","Consolidation and drug-margin incentives"]},"route":"/technologies/community-oncology-networks/","neighbours":{"section":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"technology":[{"id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","route":"/technologies/ai-trial-matching/"},{"id":"oncology-real-world-data","kind":"technology","name":"Oncology EHR and real-world data platforms","route":"/technologies/oncology-real-world-data/"}],"company":[{"id":"cardinal-health","kind":"company","name":"Cardinal Health Nuclear & Precision Health Solutions","route":"/companies/cardinal-health/"},{"id":"florida-cancer-specialists","kind":"company","name":"Florida Cancer Specialists & Research Institute","route":"/companies/florida-cancer-specialists/"},{"id":"mckesson-us-oncology","kind":"company","name":"McKesson / The US Oncology Network","route":"/companies/mckesson-us-oncology/"},{"id":"oneoncology","kind":"company","name":"OneOncology","route":"/companies/oneoncology/"},{"id":"sarah-cannon-research-institute","kind":"company","name":"Sarah Cannon Research Institute","route":"/companies/sarah-cannon-research-institute/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"term":[{"id":"340b-program","kind":"term","name":"340B Drug Pricing Program","route":"/terms/340b-program/"},{"id":"accrual","kind":"term","name":"Accrual and enrolment","route":"/terms/accrual/"},{"id":"centralisation","kind":"term","name":"Centralisation and high-volume centres","route":"/terms/centralisation/"},{"id":"step-up-dosing","kind":"term","name":"Step-up dosing (T-cell engagers)","route":"/terms/step-up-dosing/"}],"paper":[{"id":"paper-unger-trial-participation-barriers-jnci-2019","kind":"paper","name":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes","route":"/key-papers/paper-unger-trial-participation-barriers-jnci-2019/"}]}}